Is Tonix Pharmaceuticals Holding Corp. (TNXP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.7% / 30% | 57.4% / 30% | 4.7% / 30% | 543.75% / 5% | ✗ NOT HALAL |
| DJIM | 4.7% / 33% | 57.4% / 33% | 4.7% / 33% | 543.75% / 5% | ✗ NOT HALAL |
| MSCI | 5.0% / 33% | 60.6% / 33% | 5.0% / 33% | 543.75% / 5% | ✗ NOT HALAL |
| S&P | 4.7% / 33% | 57.4% / 33% | 4.7% / 33% | 543.75% / 5% | ✗ NOT HALAL |
| FTSE | 5.0% / 33% | 60.6% / 33% | 5.0% / 50% | 543.75% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 49.3% | |
| Operating Margin | -895.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -64.5% | |
| Return on Assets (ROA) | -35.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$100M |
| Free Cash Flow | -$103M |
| Total Debt | $1M |
| Debt-to-Equity | 0.5 |
| Current Ratio | 7.4 |
| Total Assets | $277M |
Price & Trading
| Last Close | $13.75 |
| 50-Day MA | $15.43 |
| 200-Day MA | $24.60 |
| Avg Volume | 411K |
| Beta | 1.9 |
|
52-Week Range
$12.70
| |
About Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tonix Pharmaceuticals Holding Corp. (TNXP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tonix Pharmaceuticals Holding Corp. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tonix Pharmaceuticals Holding Corp.'s debt ratio?
Tonix Pharmaceuticals Holding Corp.'s debt ratio is 4.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.0%.
What are Tonix Pharmaceuticals Holding Corp.'s key financial metrics?
Tonix Pharmaceuticals Holding Corp. has a market capitalization of $173M, and revenue of $13M. Return on equity stands at -64.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.